Zacks Investment Research upgraded shares of Compugen (NASDAQ:CGEN) from a sell rating to a hold rating in a research report released on Tuesday morning.

According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “

Separately, ValuEngine lowered Compugen from a sell rating to a strong sell rating in a research report on Sunday, December 31st.

Compugen (CGEN) opened at $2.80 on Tuesday. Compugen has a 1 year low of $2.25 and a 1 year high of $5.40.

A hedge fund recently raised its stake in Compugen stock. Ark Investment Management LLC boosted its stake in shares of Compugen Ltd. (NASDAQ:CGEN) by 104.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 560,103 shares of the biotechnology company’s stock after acquiring an additional 285,653 shares during the quarter. Ark Investment Management LLC owned 1.10% of Compugen worth $2,128,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 17.43% of the stock is currently owned by institutional investors.

WARNING: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at

About Compugen

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.

Get a free copy of the Zacks research report on Compugen (CGEN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related stocks with our FREE daily email newsletter.